SUPPLEMENTARY METHODS

Genotype data quality control procedures in CCSS and SJLIFE

For SJLIFE participants and participants in CCSS whose primary cancer was diagnosed between 1987 and 1999 (Expansion Cohort), paired-end whole-genome sequencing was performed using the Illumina HiSeq X10 or NovaSeq sequencers. Sequencing reads were mapped to the GRCh38 human genome assembly using the Burrows-Wheeler Aligner algorithm¹ (BWA-MEM). Variant calls were processed with GATK v3.4.0² and BCFtools³ using recommended best practices. PLINK v1.90b⁴ and VCFtools v0.1.13⁵ were used to perform additional quality control, applying the following sample exclusion criteria: excess missingness (\geq 5%), cryptic relatedness (pi-hat>0.25), and excess heterozygosity (>3 standard deviations from sample mean). Variants with minimum genotype quality score <20, minimum mean read depth <10, HWE test P<1×10⁻¹⁰ and >10% missingness across samples were removed.

For CCSS participants whose primary cancer was diagnosed before 1987 (Original Cohort), DNA was genotyped at the Cancer Genomics Research Laboratory of the National Cancer Institute (Bethesda, MD) using the Illumina HumanOmni5Exome array. Genotypes were called with Genotyping Module v1.9 (Illumina GenomeStudio software v2011.1). Samples with excess missingness (\geq 8%), heterozygosity (<0.11 or >0.16), sex discordance (X chromosome heterozygosity >5% for males or <20% for females), and cryptic relatedness (identity-bydescent sharing for first relatives, i.e., >0.70) were removed. Variants with Hardy Weinberg equilibrium (HWE) test P<0.001, call rates ≤97%, and of ambiguous strand (A/T or C/G) were removed. After this quality control process, genotypes were imputed via the Michigan Imputation Server using Minimac3⁶ and the Haplotype Reference Consortium r1.1 reference panel. Genetic variants with low imputation quality (r^2 <0.8) were removed.

Genetic ancestry

Procedures to identify the genetic ancestry of SJLIFE and CCSS samples have been described elsewhere.^{7,8} Briefly, an EIGENSTRAT-based principal component analysis⁹ was performed with PLINK v1.90b for each cohort by combining cohort samples with samples from 1000 Genomes (1000G) global reference populations. Samples with principal component scores ±3 SD of the means of the first two principal components in the 1000G European or African populations were considered to be of European or African ancestry, respectively. Principal components were then computed using independent common variants for each genetically inferred ancestral population in SJLIFE and CCSS for inclusion in multivariable models.

Variant annotation for rare variant association analyses

Methods to pool or collapse rare variants are instrumental in association studies of rare variation, enhancing power by examining the combined effect of different rare variants at a given locus¹⁰⁻¹². To this end, genic annotations were obtained from the ANNOVAR¹³ based on the RefSeq gene model, which included the 3' untranslated region (UTR) and 5' UTR, and intron, splicing, frameshift, synonymous, non-synonymous, stopgain, stoploss and upstream (within 5 kilobases of the start of a gene) regions. We categorized rare/low-frequency variants as pathogenic or likely pathogenic that were: (1) protein truncating variants (PTVs), or coding variants that are annotated to cause frameshift, stoploss, stopgain and splicing site changes as predicted by by SnpEff¹⁴ (version 5.1d); or (2) pathogenic or likely-pathogenic per ClinVar¹⁵ predictions.

Functional/regulatory annotations of genetic variants

Coding and regulatory consequences of replicated index variants, including Combined Annotation Dependent Depletion¹⁶ (CADD) scores predicting variant deleteriousness, were annotated using the Ensembl Variant Effect Predictor¹⁷ (VEP v99). Significant associations with gene expression, i.e., expression quantitative trait loci (eQTLs; FDR<5%), and DNA methylation levels, i.e., methylation quantitative trait loci (meQTLs; FDR<5%), were identified from the Genotype-Tissue Expression¹⁸ (GTEx v8) project, eQTLGen Consortium¹⁹, and BIOS Consortium²⁰ (BIOS QTL) databases. Chromatin state annotations for regulatory states (e.g., promoters, enhancers, transcription, Polycomb repressed) based on the 15-state ChromHMM model trained on 12 epigenetic marks for 127 epigenomes²¹ were obtained from the Roadmap Epigenomics Consortium. We used pooled chromatin state annotations for any promoter (states 1-2, 10), transcription (states 3-5), enhancer (states 6-7, 11-12), and polycomb repressed (states 13-14) states among relevant epigenomes (liver [E066, E118]; pancreas [E087, E098]; fat [E023, E025, E063]).

SUPPLEMENTARY REFERENCES

1. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv [Internet]. 2013 Jan 1, 2022:[1-3 pp.].

2. McKenna A, Hanna M, Banks E *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010;20(9):1297-303.

3. Li H, Handsaker B, Wysoker A *et al.* The sequence alignment/map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9.

4. Purcell S, Neale B, Todd-Brown K *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81(3):559-75.

5. Danecek P, Auton A, Abecasis G *et al.* The variant call format and VCFtools. *Bioinformatics*. 2011;27(15):2156-8.

6. Das S, Forer L, Schönherr S *et al.* Next-generation genotype imputation service and methods. *Nat Genet*. 2016;48(10):1284-7.

7. Sapkota Y, Turcotte LM, Ehrhardt MJ *et al.* Genome-Wide Association Study in Irradiated Childhood Cancer Survivors Identifies HTR2A for Subsequent Basal Cell Carcinoma. *J Invest Dermatol.* 2019.

8. Sapkota Y, Cheung YT, Moon W *et al.* Whole-genome sequencing of childhood cancer survivors treated with cranial radiation therapy identifies 5p15. 33 locus for stroke: A report from the St. Jude Lifetime Cohort study. *Clinical Cancer Research*. 2019:clincanres. 1231.2019.

9. Price AL, Patterson NJ, Plenge RM *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet.* 2006;38(8):904.

10. Li B & Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *The American Journal of Human Genetics*. 2008;83(3):311-21.

11. Price AL, Kryukov GV, de Bakker PI *et al.* Pooled association tests for rare variants in exon-resequencing studies. *The American Journal of Human Genetics*. 2010;86(6):832-8.

Lee S, Abecasis GR, Boehnke M & Lin X. Rare-variant association analysis: study designs and statistical tests. *The American Journal of Human Genetics*. 2014;95(1):5-23.
 Wang K, Li M & Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38(16):e164-e.

14. Cingolani P, Platts A, Wang LL *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. *Fly*. 2012;6(2):80-92.

15. Landrum MJ, Chitipiralla S, Brown GR *et al.* ClinVar: improvements to accessing data. *Nucleic Acids Res*. 2020;48(D1):D835-D44.

16. Kircher M, Witten DM, Jain P *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):310.

17. McLaren W, Gil L, Hunt SE *et al.* The ensembl variant effect predictor. *Genome Biol*. 2016;17(1):122.

18. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science*. 2015;348(6235):648-60.

19. Võsa U, Claringbould A, Westra H-J *et al.* Large-scale cis-and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat Genet.* 2021;53(9):1300-10.

20. Bonder MJ, Luijk R, Zhernakova DV *et al.* Disease variants alter transcription factor levels and methylation of their binding sites. *Nat Genet*. 2017;49(1):131.

21. Kundaje A, Meuleman W, Ernst J *et al.* Integrative analysis of 111 reference human epigenomes. *Nature*. 2015;518(7539):317-30.

SUPPLEMENTARY FIGURES AND TABLES



Supplementary Figure 1: Manhattan plots for SNP association test p-values among SJLIFE survivors of European (EUR; top panel) and African (AFR; bottom panel) genetic ancestry. The Manhattan plots illustrate $-\log_{10}$ p-values for SNP associations with diabetes mellitus risk (y-axis) against SNP genomic positions (x-axis). The solid red line signifies the genome-wide significance threshold (log-transformed P=5x10⁻⁸).



Supplementary Figure 2: Quantile-quantile (QQ) plot for SNP association test p-values from the SJLIFE discovery GWAS. European (EUR) and African (AFR) genetic ancestry QQ plots are shown on the left and right panels, respectively. The QQ plots show observed –log₁₀ p-values (y-axis) against those expected under the null distribution of no association (x-axis), as well as the genomic inflation factor (lambda).



Supplementary Figure 3: LocusZoom plots of novel diabetes mellitus risk loci from common variant association analyses among SJLIFE survivors of European ancestry. Single variant association test p-values from discovery analyses are shown (-log₁₀ scale) for variants within a 500-kilobase window around the index variant at each locus (annotated in each panel). SNPs are color coded by their magnitude of linkage disequilibrium (LD, measured as r²) with the most significantly associated variant in the window in the 1000 Genomes European reference panel.



Supplementary Figure 4: LocusZoom plot of the novel diabetes mellitus risk loci at 8q11.21 with African ancestry linkage disequilibrium patterns. SNPs are color coded by their magnitude of linkage disequilibrium (LD, measured as r^2) with the most significantly associated variant in the window in the 1000 Genomes African reference panel.



Supplementary Figure 5: LocusZoom plot of the novel diabetes mellitus risk loci at 5p15.2 with African and European ancestry linkage disequilibrium patterns. SNPs are color coded by their magnitude of linkage disequilibrium (LD, measured as r^2) with the most significantly associated variant in the window in the SJLIFE AFR discovery GWAS, in both SJLIFE AFR (top) and EUR (bottom) samples.

Supplementary Table 1: Multivariable model for diabetes mellitus risk with clinical risk factors only for SJLIFE participants of European or African genetic ancestry

	SJ	LIFE EUR (N=3,1	02)	SJ	JLIFE AFR (N=5	74)
Variables	OR	95% CI	Р	OR	95% CI	Р
Sex	1.23	0.94-1.62	0.13	0.81	0.40-1.63	0.56
Age at cancer diagnosis, per 5 years	0.94	0.83-1.06	0.29	0.61	0.43-0.87	6.5x10 ⁻³
Age at follow-up, per 10 years	1.91	1.67-2.19	1.2x10 ⁻²⁰	2.52	1.80-3.54	8.0x10 ⁻⁸
Adjusted body mass index, per 5 kg/m ²	1.56	1.44-1.69	3.8x10 ⁻²⁸	1.45	1.18-1.78	3.9x10 ⁻⁴
Maximum cumulative abdominal						
radiation dose, per 10 Gy	1.23	1.10-1.38	3.6x10 ⁻⁴	1.23	0.91-1.66	0.17
Alkylating agent CED dose, per g/m ²	0.99	0.97-1.01	0.24	0.95	0.89-1.01	0.11
Any alkylating agents ^a	1.35	1.02-1.80	0.039	0.52	0.25-1.08	0.081

Abbreviations: SJLIFE, St. Jude Lifetime Cohort Study; EUR, European genetic ancestry; AFR, African genetic ancestry; m, meters; g, grams; kg, kilograms; Gy, Gray; CED, cyclophosphamide equivalent dose; OR, odds ratio; CI, confidence interval; P, p-value.

a. Adjusted ORs are based on multivariable models with the same set of adjustment covariates used in all genetic analyses (see previous rows), with the exception of a threshold-dose variable definition for alkylating agents (receipt of any alkylating agents vs. none).

Supplementary Table 2: Demographic and clinical characteristics of childhood cancer survivors in CCSS

	CC	SS original cohort	CCS	S expansion cohort
		(N=3902)		(N=2063)
Characteristic	Ν	%	Ν	%
Sex				
Male	1862	47.7	966	48.0
Female	2040	52.3	1097	52.0
Age at follow up (in years)				
<25	151	3.9	516	28.2
25-34	941	24.1	1100	54.3
35-44	1513	38.8	428	16.8
≥45	1297	33.2	19	0.7
Body mass index (kg/m ²)				
≤25	1609	41.2	1002	48.8
>25 to ≤30	1268	32.5	599	29.6
>30 to ≤40	834	21.4	387	18.8
>40	191	4.9	75	2.9
Developed diabetes mellitus ^a	223	5.7	47	2.3
Age at cancer diagnosis (in years)				
<5	1536	39.4	721	40.4
5-9	848	21.7	485	26.1
10-14	819	21.0	520	20.5
≥15	699	17.9	337	13.0
Childhood cancer diagnosis				
Leukemias	1187	30.4	442	39.4
Central nervous system tumors	553	14.2	528	19.7
Hodgkin lymphoma	475	12.2	248	9.3
Non-Hodgkin lymphoma	306	7.8	191	7.1
Kidney tumors	405	10.4	203	7.6
Soft tissue sarcomas	362	9.3	107	4.0
Other	614	15.7	344	12.9
Cancer treatments				
Any abdominal radiation therapy (RT)	983	25.2	347	13.7
Any alkylating agents	1736	44.5	1083	52.7
Dosages: Median (IQR) ^b				
Abdominal RT tumor dose (cGy)	983	3000 (2000-3600)	347	2300 (1200-3550)
Alkylating agents (CED, mg/m ²)	1736	8665 (4371-13919)	1083	7167 (3948-12187)

Abbreviations: CCSS, Childhood Cancer Survivor Study; IQR, interquartile range; RT, radiation therapy; CED, cyclophosphamide equivalent dose; mg, milligrams; m, meters; kg, kilograms. Percentages reflect primary cancer diagnosis sampling weights. a. Self-reported diabetes mellitus requiring medication was evaluated in CCSS.

Treatment dose distribution statistics are provided for childhood cancer survivors who received any of the specified treatments b. and had non-missing dosage information.

				SJLIFE EUR			SJLIFE AFR			SJLIFE EUR + AFR meta-analysis		
Chr	BP	EA	NEA	EAF	OR (95% CI)	Р	EAF	OR (95% CI)	Р	OR	Р	Phet
			ΑΑΑΑΤΑΑΑΑΤΑΑΑΑΤΑ		1.99			2.30		2.05		
2	2434309	Α	AAATAAAAAC	0.10	(1.49-2.66)	2.8x10⁻ ⁶	0.17	(1.30-4.07)	4.2x10⁻³	(1.59-2.65)	4.5x10⁻ ⁸	0.66
					1.96			4.14		2.04		
2	2460867	С	Т	0.13	(1.51-2.56)	6.0x10 ⁻⁷	0.03	(1.35-12.69)	0.013	(1.58-2.64)	5.6x10 ⁻⁸	0.20
					1.95			4.24		2.03		
2	2462940	Α	G	0.13	(1.49-2.54)	8.0x10 ⁻⁷	0.03	(1.38-13.06)	0.012	(1.57-2.63)	7.4x10 ⁻⁸	0.19
					1.98			0.54		1.60		
8	50635641	Т	С	0.15	(1.55-2.54)	5.1x10⁻ ⁸	0.38	(1.31-0.93)	0.027	(1.28-2)	4.5x10⁻⁵	2.3x10 ⁻⁵
					1.98			0.54		1.59		
8	50636999	С	Т	0.15	(1.55-2.53)	5.6x10 ⁻⁸	0.38	(1.31-0.93)	0.027	(1.27-1.99)	5.2x10⁻⁵	2.2x10 ⁻⁵
					1.99			0.57		1.61		
8	50637285	Α	Т	0.15	(1.55-2.54)	4.7x10 ⁻⁸	0.37	(1.33-0.98)	0.042	(1.28-2.01)	3.5x10⁻⁵	4.1x10 ⁻⁵
					1.98			0.54		1.59		
8	50637444	Α	G	0.15	(1.55-2.53)	5.4x10⁻ ⁸	0.38	(1.31-0.93)	0.026	(1.27-1.99)	5.2x10⁻⁵	2.1x10 ⁻⁵
					1.99			0.53		1.59	_	_
8	50638825	G	A	0.15	(1.56-2.55)	4.4x10 ⁻⁸	0.38	(1.30-0.91)	0.022	(1.27-2)	4.8x10⁻⁵	1.6x10 ⁻⁵
					1.94	_		0.55		1.57	_	_
8	50641552	Α	G	0.15	(1.52-2.48)	1.4x10 ⁻⁷	0.37	(1.32-0.95)	0.032	(1.25-1.97)	8.8x10⁻⁵	4.0x10 ⁻⁵
					1.94	_		0.55		1.57	_	_
8	50643118	Т	G	0.15	(1.52-2.48)	1.4x10 ⁻⁷	0.37	(1.32-0.95)	0.032	(1.25-1.97)	8.7x10⁻⁵	4.1x10 ⁻⁵
					1.73			0.58		1.45		
8	50644980	Α	G	0.18	(1.37-2.18)	4.2x10 ⁻⁶	0.40	(1.34-0.99)	0.046	(1.17-1.8)	6.3x10 ⁻⁴	2.4x10 ⁻⁴
					1.68			0.44		1.41		
8	50660409	G	GAAAA	0.21	(1.35-2.09)	4.0x10 ⁻⁶	0.47	(1.25-0.77)	4.5x10⁻³	(1.15-1.73)	1.0x10 ⁻³	1.7x10⁵
					1.66			0.59		1.45		
8	50661918	G	C	0.30	(1.35-2.04)	1.2x10⁵	0.64	(1.35-1.00)	0.048	(1.2-1.75)	1.3x10⁴	3.1x10⁴
					1.74	7		0.57		1.48		
8	50666979	A	G	0.21	(1.40-2.16)	6.4x10⁻′	0.51	(1.33-0.97)	0.037	(1.21-1.81)	1.3x10 ^{-₄}	1.5x10 ^{-₄}
		_			1.71			0.57		1.46		
8	50667110	A	G	0.21	(1.37-2.12)	1.5x10⁵	0.60	(1.33-0.97)	0.039	(1.19-1.79)	2.3x10⁴	1.9x10 ^{-₄}
		-	_		1.71			0.57		1.45		
8	50667850	G	Т	0.21	(1.37-2.12)	1.5x10⁵	0.61	(1.33-0.96)	0.035	(1.19-1.78)	2.7x10⁴	1.5x10 ^{-₄}
		-	_		1.72			0.56		1.45	0 = 101	1 0 101
8	50671413	С	Т	0.21	(1.38-2.13)	1.2x10 ⁻ ⁰	0.61	(1.33-0.94)	0.029	(1.19-1.78)	2.7x10⁴	1.0x10 ⁻
					1.69			0.44		1.53		
8	50671938	A	G	0.21	(1.36-2.10)	3.0x10⁵	0.19	(1.20-0.97)	0.043	(1.24-1.9)	7.3x10⁵	1.4x10⁻³
		_			1.72			0.55		1.46	a = 1a 1	0.0.105
8	506/2410	Г	A	0.21	(1.38-2.14)	1.0x10⁵	0.61	(1.32-0.92)	0.024	(1.19-1.78)	2.5x10 ^{-₄}	8.0x10⁻°
	50070005		_		1.73	0 5 107	o = /	0.57	0.00-	1.48	4 0 10 1	10.00
8	50672830	С	ſ	0.21	(1.39-2.15)	8.5x10 ^{-/}	0.51	(1.33-0.97)	0.037	(1.21-1.81)	1.6x10 ^{-₄}	1.6x10 ^{-₄}
6	5007000	~		0.04	1.71	4 5 406	0.04	0.55	0.001	1.45	0.0.101	0.0.105
8	50673224	G	A	0.21	(1.37-2.12)	1.5x10 ⁻⁰	0.61	(1.32-0.92)	0.024	(1.18-1.//)	3.2x10**	9.0x10 ⁻⁵
8	50674706	G	A	0.21	1.72	9.9x10 ⁻⁷	0.61	0.55	0.024	1.46	2.5x10⁴	7.9x10⁵

Supplementary Table 3: SJLIFE trans-ancestry meta-analysis results for top genetic associations with diabetes mellitus risk (100-kb window, P<5x10⁻⁶)

	F			SJLIFE EUR				SJLIFE AFR			SJLIFE EUR + AFR meta-analysis		
Chr	BP	EA	NEA	EAF	OR (95% CI)	Р	EAF	OR (95% CI)	Р	OR	Р	Phet	
					(1.39-2.14)			(1.32-0.92)		(1.19-1.78)			
					1.71			0.55		1.45			
8	50675283	G	А	0.21	(1.37-2.12)	1.4x10 ⁻⁶	0.61	(1.32-0.92)	0.024	(1.18-1.77)	3.1x10 ⁻⁴	8.9x10 ⁻⁵	
					1.71			0.44		1.55			
8	50676103	С	Т	0.21	(1.37-2.12)	1.7x10 ⁻⁶	0.19	(1.20-0.98)	0.044	(1.26-1.91)	4.4x10 ⁻⁵	1.3x10 ⁻³	
					1.71			0.44		1.55			
8	50676751	G	Т	0.21	(1.37-2.12)	1.6x10 ⁻⁶	0.19	(1.20-0.98)	0.044	(1.26-1.91)	4.3x10 ⁻⁵	1.3x10 ⁻³	
					1.68			0.57		1.42			
8	50681567	G	A	0.20	(1.34-2.09)	5.0x10 ⁻⁶	0.61	(1.34-0.96)	0.034	(1.16-1.74)	7.4x10 ⁻⁴	1.9x10 ⁻⁴	
					2.26			2.99		2.43			
19	22614854	G	A	0.05	(1.60-3.20)	4.1x10 ⁻⁶	0.22	(1.66-5.37)	2.6x10 ⁻⁴	(1.80-3.28)	5.7x10 ⁻⁹	0.43	
					2.28			2.23		2.27	_		
19	22614973	Α	G	0.05	(1.61-3.24)	3.7x10 ⁻⁶	0.16	(1.17-4.25)	0.014	(1.67-3.09)	1.7x10 ⁻⁷	0.95	
					2.26			2.64		2.36			
19	22615242	Т	С	0.05	(1.59-3.19)	4.4x10 ⁻⁶	0.22	(1.51-4.62)	6.6x10 ⁻⁴	(1.76-3.17)	1.2x10 ⁻⁸	0.64	
					2.26			2.43		2.31			
19	22615378	Α	G	0.05	(1.60-3.20)	4.3x10 ⁻⁶	0.23	(1.41-4.20)	1.4x10 ⁻³	(1.72-3.09)	2.3x10 ⁻⁸	0.82	
					2.26			2.43		2.31			
19	22615432	С	A	0.05	(1.60-3.20)	4.3x10 ⁻⁶	0.23	(1.41-4.19)	1.5x10 ⁻³	(1.72-3.09)	2.3x10 ⁻⁸	0.83	

Abbreviations: SJLIFE, St. Jude Lifetime Cohort Study; Chr, chromosome; BP, base position, GRCh38 (hg38) build; EA, effect (risk) allele; NEA, non-effect (reference) allele; EUR, European genetic ancestry; AFR, African genetic ancestry; OR, odds ratio; CI, confidence interval; P, p-value.

Supplementary Table 4: CCSS replication results for top genetic associations with risk for self-reported diabetes mellitus requiring oral medications or insulin (European genetic ancestry)

				CC	SS Original (N=223 cas	ses)	CCSS Expansion (N=47 cases)			
Chr	BP	EA	NEA	EAF	OR (95% CI)	Р	EAF	OR (95% CI)	Р	
2	2460867	С	Т	0.14	1.20 (0.91-1.59)	0.19	0.13	1.03 (0.52-2.07)	0.92	
2	2462940	А	G	0.14	1.21 (0.92-1.60)	0.17	0.13	1.03 (0.52-2.07)	0.93	
5	9843018	С	Т				0.01	1.02 (0.13-7.77)	0.98	
5	9841183	G	С	0.07	1.48 (1.06-2.07)	0.021	0.07	0.79 (0.31-2.03)	0.63	
5	9853032	С	G				0.01	0.96 (0.13-7.36)	0.97	
8	50635641	Т	С	0.16	1.39 (1.09-1.78)	9.0x10 ⁻³	0.15	0.95 (0.52-1.73)	0.88	
8	50636999	С	Т	0.16	1.39 (1.08-1.77)	9.4x10 ⁻³	0.15	0.95 (0.52-1.74)	0.88	
8	50637285	А	Т	0.16	1.39 (1.08-1.77)	9.4x10 ⁻³	0.15	0.95 (0.52-1.73)	0.87	
8	50637444	А	G	0.16	1.39 (1.08-1.77)	9.4x10 ⁻³	0.15	0.95 (0.52-1.74)	0.88	
8	50638825	G	А	0.16	1.39 (1.08-1.77)	9.4x10 ⁻³	0.15	0.95 (0.52-1.74)	0.88	
8	50641552	А	G	0.16	1.39 (1.08-1.77)	9.4x10 ⁻³	0.15	0.95 (0.52-1.74)	0.88	
8	50643118	Т	G	0.16	1.39 (1.08-1.77)	9.4x10 ⁻³	0.15	0.95 (0.52-1.74)	0.88	
8	50644980	А	G	0.18	1.26 (0.98-1.60)	0.07	0.18	1.00 (0.58-1.73)	1.00	
8	50661918	G	С	0.69	0.89 (0.72-1.09)	0.26	0.70	0.79 (0.54-1.14)	0.21	
8	50666979	А	G	0.22	1.20 (0.96-1.50)	0.11	0.22	1.56 (1.01-2.40)	0.045	
8	50667110	А	G	0.22	1.21 (0.97-1.51)	0.10	0.22	1.56 (1.01-2.39)	0.044	
8	50667850	G	Т	0.22	1.21 (0.97-1.51)	0.10	0.22	1.33 (0.84-2.10)	0.23	
8	50672410	Т	А	0.22	1.21 (0.97-1.51)	0.10	0.22	1.32 (0.83-2.10)	0.23	
8	50672830	С	Т	0.22	1.21 (0.96-1.51)	0.10	0.22	1.33 (0.84-2.11)	0.23	
8	50673224	G	А	0.22	1.21 (0.97-1.51)	0.10	0.22	1.32 (0.83-2.10)	0.23	
8	50674706	G	А	0.22	1.21 (0.97-1.51)	0.10	0.22	1.32 (0.83-2.10)	0.23	
8	50675283	G	А	0.22	1.21 (0.97-1.51)	0.10	0.22	1.43 (0.91-2.26)	0.12	
8	50676103	С	Т	0.22	1.2 (0.96-1.49)	0.12	0.21	1.34 (0.84-2.14)	0.22	
8	50676751	G	Т	0.22	1.19 (0.95-1.49)	0.13	0.21	1.45 (0.91-2.30)	0.11	
8	50681567	G	А	0.21	1.17 (0.93-1.47)	0.18	0.20	1.54 (0.97-2.45)	0.07	
19	22614854	G	А	0.06	1.17 (0.77-1.77)	0.46	0.06	0.76 (0.31-1.87)	0.55	
19	22614973	А	G	0.06	1.17 (0.77-1.78)	0.46	0.06	0.77 (0.31-1.91)	0.57	
19	22615242	Т	С	0.06	1.17 (0.77-1.77)	0.46	0.06	0.76 (0.31-1.88)	0.55	
19	22615378	А	G	0.06	1.17 (0.77-1.77)	0.46	0.06	0.76 (0.31-1.87)	0.55	
19	22615432	С	А	0.06	1.17 (0.77-1.77)	0.46	0.06	0.76 (0.31-1.88)	0.55	

Abbreviations: CCSS, Childhood Cancer Survivor Study; Chr, chromosome; BP, base position, GRCh38 (hg38) build; EA, effect (risk) allele; NEA, non-effect (reference) allele; OR, odds ratio; CI, confidence interval; P, p-value.

				C	CSS Ori	ginal (N=108 case	s)	CCSS Expansion (N=25 cases)			
Chr	BP	EA	NEA	EAF	OR	CI	Р	EAF	OR	CI	Р
2	2460867	С	Т	0.14	1.45	1.00-2.10	0.047	0.13	0.91	0.38-2.14	0.82
2	2462940	А	G	0.14	1.49	1.03-2.14	0.033	0.13	0.91	0.38-2.14	0.82
8	50635641	Т	С	0.16	1.56	1.12-2.17	7.9x10 ⁻³	0.15	0.52	0.23-1.20	0.12
8	50636999	С	Т	0.16	1.56	1.12-2.17	8.1x10 ⁻³	0.15	0.52	0.22-1.20	0.13
8	50637285	А	Т	0.16	1.56	1.12-2.17	8.1x10 ⁻³	0.15	0.52	0.22-1.20	0.13
8	50637444	А	G	0.16	1.56	1.12-2.17	8.1x10 ⁻³	0.15	0.52	0.22-1.20	0.13
8	50638825	G	А	0.16	1.56	1.12-2.17	8.1x10 ⁻³	0.15	0.52	0.22-1.20	0.13
8	50641552	Α	G	0.16	1.56	1.12-2.17	8.1x10 ⁻³	0.15	0.52	0.22-1.20	0.13
8	50643118	Т	G	0.16	1.56	1.12-2.17	8.1x10 ⁻³	0.15	0.52	0.22-1.20	0.13
8	50644980	Α	G	0.18	1.43	1.04-1.99	0.029	0.18	0.83	0.37-1.83	0.64
8	50661918	G	С	0.69	0.88	0.66-1.17	0.36	0.70	1.09	0.61-1.96	0.77
8	50666979	А	G	0.22	1.08	0.79-1.49	0.63	0.22	1.08	0.54-2.15	0.82
8	50667110	А	G	0.22	1.1	0.80-1.51	0.55	0.22	1.08	0.54-2.16	0.82
8	50667850	G	Т	0.22	1.1	0.80-1.51	0.55	0.22	1.08	0.55-2.16	0.82
8	50672410	Т	А	0.22	1.1	0.80-1.51	0.55	0.22	1.08	0.54-2.16	0.82
8	50672830	С	Т	0.22	1.09	0.79-1.49	0.61	0.21	1.09	0.55-2.16	0.82
8	50673224	G	А	0.22	1.1	0.80-1.51	0.55	0.22	1.08	0.54-2.16	0.82
8	50674706	G	А	0.22	1.1	0.80-1.51	0.55	0.22	1.08	0.54-2.15	0.82
8	50675283	G	А	0.22	1.1	0.80-1.51	0.55	0.22	1.08	0.54-2.16	0.82
8	50676103	С	Т	0.22	1.06	0.77-1.46	0.71	0.21	1.09	0.55-2.17	0.81
8	50676751	G	Т	0.22	1.07	0.77-1.47	0.70	0.21	1.09	0.55-2.17	0.81
8	50681567	G	А	0.21	1.1	0.80-1.52	0.56	0.20	1.17	0.59-2.31	0.66
19	22614854	G	А	0.06	1.04	0.57-1.89	0.91	0.06	0.75	0.22-2.60	0.65
19	22614973	Α	G	0.06	1.04	0.57-1.89	0.90	0.06	0.77	0.22-2.67	0.68
19	22615242	Т	С	0.06	1.04	0.57-1.89	0.91	0.06	0.75	0.22-2.60	0.65
19	22615378	Α	G	0.06	1.04	0.57-1.89	0.91	0.06	0.75	0.22-2.60	0.65
10	22615432	C	Δ	0.06	1 04	0 57-1 89	0.91	0.06	0.76	0 22-2 61	0.66

Supplementary Table 5: CCSS replication results for top genetic associations with self-reported insulin-dependent diabetes mellitus risk (European genetic ancestry)

 19
 22615432
 C
 A
 0.06
 1.04
 0.57-1.89
 0.91
 0.06
 0.76
 0.22-2.61
 0.66

 Abbreviations: CCSS, Childhood Cancer Survivor Study; Chr, chromosome; BP, base position, GRCh38 (hg38) build; EA, effect (risk) allele; NEA, non-effect (reference) allele; OR, odds ratio; CI, confidence interval; P, p-value.
 0.91
 0.06
 0.76
 0.22-2.61
 0.66

Supplementary Table 6: Associations between index variants and self-reported and diagnosed type 2 diabetes risk in the general population (UK Biobank Study)

			Self-reported	1 T2D (2,292	cases)	
	Minor	UKB				
Variants	allele	MAF	N	Beta	SE	Р
2:2438081:AAAATAAAATAAAATAAAATAAAAAAAAAAAAAAAAA	Α	0.20	361141	2.4x10 ⁻⁴	2.4x10 ⁻⁴	0.32
8:51551385:A:G	G	0.15	361141	9.0x10 ⁻⁵	2.6x10 ⁻⁴	0.73
19:22797656:A:G	G	0.06	361141	1.1x10 ⁻³	4.1x10 ⁻⁴	6.6x10 ⁻³
5:9843018:T:C			N	ot present		
Variants			ICD T2	D (888 cases	5)	
2:2438081:AAAATAAAATAAAATAAAATAAAAAC:A	Α	0.20	361194	4.4x10 ⁻⁴	1.5x10 ⁻⁴	3.6x10 ⁻³
8:51551385:A:G	G	0.15	361194	2.5x10 ⁻⁴	1.6x10 ⁻⁴	0.12
19:22797656:A:G	G	0.06	361194	3.4x10 ⁻⁴	2.6x10 ⁻⁴	0.18
5:9843018:T:C			N	ot present		

Variants included in genes are annotated in chromosome:base position:non-effect allele.effect allele format, GRCh37 build. Selfreported T2D summary statistics were obtained from file 20002_1223.gwas.imputed_v3.both_sexes.tsv.bgz and ICD-10-coded T2D summary statistics were obtained from file E4_DM2.gwas.imputed_v3.both_sexes.tsv.bgz.

Abbreviations: UKB, UK Biobank Study; MAF, minor allele frequency; SE, standard error; P, p-value.

	Chr	BP	EA	NEA	Stratification	Ν	OR	CI	Р
	2	2434309	А	AAAATAAAATAAA ATAAAATAAAAAC	All survivors	3073	1.99	1.49-2.66	2.8x10 ⁻⁶
					No abdominal RT	2512	2.07	1.48-2.89	2.3x10 ⁻⁵
					Any abdominal RT	561	1.79	1.00-3.23	0.052
	5	9843018	С	Т	All survivors	3102	2.47	1.23-4.98	0.011
SJLIFE					No abdominal RT	2536	2.55	1.10-5.94	0.029
EUR					Any abdominal RT	566	2.01	0.56-7.24	0.29
	8	50638825	G	A	All survivors	3100	1.99	1.56-2.55	4.4x10 ⁻⁸
					No abdominal RT	2535	2.17	1.63-2.90	1.4x10 ⁻⁷
					Any abdominal RT	565	1.63	0.99-2.68	0.055
	19	22614854	G	A	All survivors	3100	2.26	1.60-3.20	4.1x10 ⁻⁶
					No abdominal RT	2534	2.24	1.47-3.41	1.8x10 ⁻⁴
					Any abdominal RT	566	2.37	1.23-4.57	0.010
	Chr	BP	FA	NFA	Stratification	N	OP	CL	P
	0111	ы	ì		Stratification			CI	1
	2	2434309	A	AAAATAAAATAAA ATAAAATAAAAAAC	All survivors	556	2.30	1.30-4.07	4.2x10 ⁻³
	2	2434309	A	ААААТААААТААА АТААААТААААААА	All survivors No abdominal RT	556 454	2.30 2.69	1.30-4.07 1.35-5.39	4.2x10 ⁻³ 5.1x10 ⁻³
	2	2434309	A	ААААТААААТААА АТААААТАААААА	All survivors No abdominal RT Any abdominal RT	556 454 102	2.30 2.69 12.10	1.30-4.07 1.35-5.39 0.98-148.94	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052
	2	2434309 9843018	A C	ААААТААААТААА АТААААТААААТААА Т	All survivors No abdominal RT Any abdominal RT All survivors	556 454 102 574	2.30 2.69 12.10 10.19	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷
SJLIFE	2	2434309 9843018	A C	ААААТААААТААА АТААААТААААТААА АТААААТАААААА	All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT	556 454 102 574 468	2.30 2.69 12.10 10.19 12.95	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21 4.09-40.97	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷ 1.3x10 ⁻⁵
SJLIFE AFR	2	2434309 9843018	A C	AAAATAAAATAAA ATAAAATAAAAAAC T	All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT	556 454 102 574 468 106	2.30 2.69 12.10 10.19 12.95 90.85	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21 4.09-40.97 2.25-3660.27	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷ 1.3x10 ⁻⁵ 0.017
SJLIFE AFR	2 5 8	2434309 9843018 50638825	A C G	AAAATAAAATAAA ATAAAATAAAAAAA TAAAAATAAAAAA	All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT All survivors	556 454 102 574 468 106 573	2.30 2.69 12.10 10.19 12.95 90.85 0.53	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21 4.09-40.97 2.25-3660.27 0.30-0.91	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷ 1.3x10 ⁻⁵ 0.017 0.022
SJLIFE AFR	2 5 8	2434309 9843018 50638825	A C G	AAAATAAAATAAA ATAAAATAAAAAAA TAAAAATAAAAAA	All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT	556 454 102 574 468 106 573 467	2.30 2.69 12.10 10.19 12.95 90.85 0.53 0.38	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21 4.09-40.97 2.25-3660.27 0.30-0.91 0.17-0.83	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷ 1.3x10 ⁻⁵ 0.017 0.022 0.016
SJLIFE AFR	2 5	2434309 9843018 50638825	A C G	AAAATAAAATAAA ATAAAAATAAAAAAA TAAAAATAAAAAA	All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT	556 454 102 574 468 106 573 467 106	2.30 2.69 12.10 10.19 12.95 90.85 0.53 0.38 0.44	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21 4.09-40.97 2.25-3660.27 0.30-0.91 0.17-0.83 0.14-1.41	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷ 1.3x10 ⁻⁵ 0.017 0.022 0.016 0.17
SJLIFE AFR	2 5 8 19	2434309 9843018 50638825 22614854	A C G G	AAAATAAAATAAA ATAAAATAAAAAAC T A A	All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT Any abdominal RT All survivors	556 454 102 574 468 106 573 467 106 573	2.30 2.69 12.10 10.19 12.95 90.85 0.53 0.38 0.44 2.99	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21 4.09-40.97 2.25-3660.27 0.30-0.91 0.17-0.83 0.14-1.41 1.66-5.37	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷ 1.3x10 ⁻⁵ 0.017 0.022 0.016 0.17 2.6x10 ⁻⁴
SJLIFE AFR	2 5 8 19	2434309 9843018 50638825 22614854	A G G	AAAATAAAATAAA ATAAAATAAAAAC T A A	All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT Any abdominal RT All survivors No abdominal RT	556 454 102 574 468 106 573 467 106 573 467	2.30 2.69 12.10 10.19 12.95 90.85 0.53 0.38 0.44 2.99 2.72	1.30-4.07 1.35-5.39 0.98-148.94 4.12-25.21 4.09-40.97 2.25-3660.27 0.30-0.91 0.17-0.83 0.14-1.41 1.66-5.37 1.28-5.78	4.2x10 ⁻³ 5.1x10 ⁻³ 0.052 5.1x10 ⁻⁷ 1.3x10 ⁻⁵ 0.017 0.022 0.016 0.17 2.6x10 ⁻⁴ 9.6x10 ⁻³

Supplementary Table 7: Abdominal radiation therapy-stratified analysis of diabetes mellitus risk index SNPs in SJLIFE survivors of European and African ancestry

Abbreviations: SJLIFE, St. Jude Lifetime Cohort Study; Chr, chromosome; BP, base position, GRCh38 (hg38) build; EA, effect (risk) allele; NEA, non-effect (reference) allele; EUR, European genetic ancestry; AFR, African genetic ancestry; RT, radiation therapy; OR, odds ratio; CI, confidence interval; P, p-value.

Supplementary	Table 8: Alkylating agent-stratified analysis of diabetes mellitus risk in	ndex
SNPs in SJLIFE	survivors of European and African ancestry	

ChrBPEANEAStratificationNORCI22434309AAAAATAAAATAAAAll survivors30731.991.49-2	P
2 2434309 A AAAATAAAATAAA All survivors 3073 1.99 1.49-2	SG 2.8v10-6
	2.0010
No abdominal RT, no AA 1154 1.87 1.07-3	0.027
No abdominal RT, high AA (≥4000 mg/m²) 1046 2.37 1.45-3	37 6.0x10 ⁻⁴
5 9843018 C T All survivors 3102 2.47 1.23-4	0.011
No AA 1351 1.27 0.32-5	0 0.73
SJLIFE Any AA 1751 3.32 1.44-7	5.0x10 ⁻³
8 50638825 G A All survivors 3100 1.99 1.56-2	55 4.4x10 ⁻⁸
No abdominal RT, no AA 1168 3.17 1.96-5	12 2.5x10 ⁻⁶
No abdominal RT, high AA (≥4000 mg/m²) 1052 1.57 1.03-2	0.038
19 22614854 G A All survivors 3100 2.26 1.60-3	20 4.1x10 ⁻⁶
No abdominal RT, no AA 1169 1.63 0.74-3	0.22
No abdominal RT, high AA (≥4000 mg/m²) 1051 3.32 1.91-5	79 2.3x10 ⁻⁵
Chr BP EA NEA Stratification N OR CI	Р
2 2434309 A AAAATAAAATAAA AII survivors 556 2.30 1.30-4	07 4.2x10 ⁻³
No AA 267 2.39 0.99-5	6 0.053
High AA (≥4000 mg/m ²) 215 3.95 1.38-1 ²	31 0.010
5 9843018 C T All survivors 574 10.19 4.12-25	21 5.1x10 ⁻⁷
SJLIFE No AA 275 10.84 3.08-38	18 2.1x10 ⁻⁴
AFR Any AA 299 17.81 3.46-9'	60 5.7x10 ⁻⁴
8 50638825 G A All survivors 573 0.53 0.30-0	0.022
No AA 274 0.62 0.29-1	34 0.23
High AA (≥4000 mg/m²) 221 0.47 0.18-1	0.11
19 22614854 G A All survivors 573 2.99 1.66-5	37 2.6x10 ⁻⁴
No AA 275 2.00 0.88-4	0.096
High AA (≥4000 mg/m²) 220 5.74 1.99-16	54 1.2x10 ⁻³

Abbreviations: SJLIFE, St. Jude Lifetime Cohort Study; Chr, chromosome; BP, base position, GRCh38 (hg38) build; EA, effect (risk) allele; NEA, non-effect (reference) allele; EUR, European genetic ancestry; AFR, African genetic ancestry; AA, alkylating agents; RT, radiation therapy; m, meters; mg, milligrams, OR, odds ratio; CI, confidence interval; P, p-value.

Supplementary Table 9: BMI-stratified analysis of the late diabetes risk index SNP in the	
chromosome 8 locus among SJLIFE and CCSS survivors	

				Study					
Chr	BP	EA	NEA	sample	BMI stratification	N	OR	95% CI	P
8	50638825	G	А	SJLIFE EUR	BMI>25 kg/m ²	1941	2.23	1.72-2.89	1.8x10 ⁻⁹
					BMI≤25 kg/m²	1159	0.90	0.42-1.94	0.80
				CCSS ORIGINAL (EUR)	BMI>25 kg/m ²	2202	1.69	1.15-2.47	7.0x10 ⁻³
					BMI≤25 kg/m²	1585	1.18	0.60-2.29	0.63

Abbreviations: SJLIFE, St. Jude Lifetime Cohort Study; CCSS, Childhood Cancer Survivor Study; Chr, chromosome; BP, base position, GRCh38 (hg38) build; EA, effect (risk) allele; NEA, non-effect (reference) allele; EUR, European genetic ancestry; BMI, body mass index; m, meters; kg, kilograms, OR, odds ratio; CI, confidence interval; P, p-value.

Cohort	Treatment	Ν	Q	OR (95% CI)	Р	Treatment	N	Q	OR (95% CI)	Р
SJLIFE AFR	No AA	275	Q2	5.68 (0.82-39.25)	0.078	No abd RT	468	Q2	14.82 (1.49-147.11)	0.021
			Q3	1.19 (0.14-9.94)	0.87			Q3	4.43 (0.42-46.50)	0.21
			Q4	4.51 (0.68-29.77)	0.12			Q4	13.48 (1.32-137.80)	0.028
			Q5	4.48 (0.72-27.76)	0.11			Q5	18.49 (1.88-181.58)	0.012
	Any AA	299	Q2	4.30 (0.37-49.84)	0.24	Any abd RT	106	Q2	0.70 (0.03-18.68)	0.83
			Q3	3.52 (0.31-40.51)	0.31	-		Q3	1.29 (0.08-20.67)	0.86
			Q4	3.14 (0.24-41.70)	0.39			Q4	0.04 (0.00-8.94)	0.24
			Q5	13.85 (1.24-154.48)	0.033			Q5	4.28 (0.40-46.27)	0.23
Combined EUR	No AA, no abd RT	3561	Q2	1.59 (0.77-3.30)	0.21	No abd RT	7171	Q2	1.66 (1.02-2.70)	0.04
			Q3	2.61 (1.34-5.10)	4.9x10 ⁻³			Q3	2.46 (1.56-3.89)	1.1x10 ⁻⁴
			Q4	2.02 (1.00-4.05)	0.048			Q4	2.49 (1.57-3.94)	1.0x10 ⁻⁴
			Q5	4.07 (2.16-7.69)	1.5x10⁻⁵			Q5	4.90 (3.19-7.52)	3.6x10 ⁻¹³
	Any AA, no abd RT	3610	Q2	1.66 (0.86-3.22)	0.13	Any abd RT	1896	Q2	0.95 (0.49-1.83)	0.87
	•		Q3	2.32 (1.23-4.38)	9.3x10 ⁻³	-		Q3	1.96 (1.09-3.54)	0.025
			Q4	2.84 (1.52-5.29)	1.0x10 ⁻³			Q4	2.67 (1.52-4.71)	6.7x10 ⁻⁴
			Q5	5.86 (3.25-10.57)	4.4x10 ⁻⁹			Q5	3.62 (2.08-6.30)	5.0x10 ⁻⁶
	Higher-dose AA, no abd RT	2695	Q2	2.00 (0.88-4.53)	0.099	Higher-dose abd RT	1431	Q2	0.94 (0.47-1.90)	0.87
	5		Q3	2.82 (1.29-6.18)	9.3x10 ⁻³	C C		Q3	2.00 (1.07-3.76)	0.031
			Q4	3.44 (1.59-7.42)	1.7x10 ⁻³			Q4	2.08 (1.11-3.88)	0.022
			Q5	8.43 (4.06-17.53)	1.1x10 ⁻⁸			Q5	3.56 (1.97-6.43)	2.5x10 ⁻⁵
SJLIFE EUR	No AA, no abd RT	1169	Q2	1.42 (0.50-4.00)	0.51	No abd RT	2536	Q2	1.46 (0.75-2.81)	0.26
			Q3	2.11 (0.81-5.51)	0.13			Q3	1.87 (1.00-3.52)	0.051
			Q4	1.55 (0.56-4.31)	0.4			Q4	2.36 (1.28-4.36)	5.9x10 ⁻³
			Q5	3.74 (1.51-9.25)	4.4x10 ⁻³			Q5	4.67 (2.62-8.32)	1.7x10 ⁻⁷
	Any AA, no abd RT	1367	Q2	1.47 (0.61-3.51)	0.39	Any abd RT	566	Q2	1.73 (0.59-5.01)	0.32
	•		Q3	1.69 (0.72-3.98)	0.23	-		Q3	3.69 (1.33-10.25́)	0.012
			Q4	2.97 (1.34-6.56)	7.3x10 ⁻³			Q4	4.20 (1.54-11.47)	5.2x10 ⁻³
			Q5	5.62 (2.60-12.15)	1.1x10⁻⁵			Q5	6.44 (2.37-17.47)	2.6x10 ⁻⁴
	Higher-dose AA, no abd RT	1052	Q2	1.86 (0.64-5.41)	0.25	Higher-dose abd RT	427	Q2	2.50 (0.75-8.31)	0.13
	-		Q3	2.33 (0.82-6.58)	0.11	_		Q3	4.57 (1.40-14.92)	0.012
			Q4	3.50 (1.33-9.26)	0.011			Q4	5.38 (1.66-17.44)	5.0x10 ⁻³
			Q5	8.83 (3.41-22.84)	7.0x10 ⁻⁶			Q5	7.92 (2.50-25.08)	4.4x10 ⁻⁴
CCSS EUR	No AA, no abd RT	2392	Q2	1.71 (0.60-4.89)	0.32	No abd RT	4635	Q2	1.69 (0.81-3.52)	0.16
			Q3	3.06 (1.18-7.99)	0.022			Q3	2.93 (1.49-5.73)	1.8x10 ⁻³
			Q4	2.43 (0.91-6.49)	0.077			Q4	2.35 (1.17-4.73)	0.016
			Q5	4.42 (1.77-11.08)	1.5x10 ⁻³			Q5	5.01 (2.63-9.54)	9.3x10 ⁻⁷
	Any AA, no abd RT	2243	Q2	1.64 (0.58-4.63)	0.35	Any abd RT	1330	Q2	0.52 (0.21-1.25)	0.14
			Q3	2.92 (1.12-7.64)	0.029			Q3	1.27 (0.61-2.66)	0.52
			Q4	2.31 (0.85-6.31)	0.10			Q4	1.94 (0.97-3.88)	0.059
		1	Q5	5.85 (2.32-14.73)	1.8x10 ⁻⁴			Q5	2.46 (1.26-4.81)	8.6x10 ⁻³
	Higher-dose AA, no abd RT	1643	Q2	1.72 (0.48-6.21)	0.41	Higher-dose abd RT	898	Q2	0.40 (0.15-1.07)	0.069
	-	1	Q3	3.06 (0.94-9.92)	0.062	_		Q3	1.19 (0.53-2.70)	0.67
		1	Q4	2.48 (0.72-8.54)	0.15			Q4	1.14 (0.51-2.55)	0.74
		1	Q5	7.23 (2.35-22.25)	5.6x10 ⁻⁴			Q5	2.18 (1.05-4.54)	0.036

Supplementary Table 10: Multi-ancestry T2D PRS (Mahajan et al.) quintile associations with diabetes mellitus risk in survivors

Abbreviations: SJLIFE, St. Jude Lifetime Cohort Study; CCSS, Childhood Cancer Survivor Study; EUR, European genetic ancestry; AFR, African genetic ancestry; AÁ, alkylating agents; abd RT, abdominal radiation therapy; Q, PRS quintile; OR, odds ratio; CI, confidence interval; P, p-value. Higher dose AA defined by doses ≥4,000 mg/m²; higher doses of abd RT defined by doses ≥2,000 cGy. **Supplementary Table 11:** Top genes enriched for rare pathogenic variants associated with diabetes mellitus risk in SJLIFE childhood cancer survivors of European genetic ancestry $(P<1x10^{-3})$

		Discovery (N=1550; 127 cases)	Replication (N=1552; 134 cases)
Gene	Genetic variants	Burden test P	Burden test P
ENSG00000254469 (<i>XNDC1N</i>)	chr11:71918924:G:A; chr11:71918995:TTTAGCAAGTTCTCTACAGGA:T	8.5x10 ⁻⁴	9.4x10 ⁻³
ZNF655	chr7:99563862:G:A; chr7:99563873:CCGCCTTCCCA:C	7.1x10 ⁻⁴	0.21

Variants included in genes are annotated in chromosome:base position:non-effect allele:effect allele format, GRCh38 build.

Supplementary Table 12: Single variant association test results for *XNDC1N* rare pathogenic/likely pathogenic variants

	Combined, SJLIFE European genetic						
	a	ncestry (N=3102)					
		OR					
Rare variant association test type	MAF (MAC)	(95% CI)	Р				
Single variant: chr11:71918924:G:A	0.002 (12)	6.30 (1.60-24.86)	8.6x10 ⁻³				
Single variant: chr11:71918995:TTTAGCAAGTTCTCTACAGGA:T	0.001 (9)	13.42 (2.77-64.99)	1.2x10 ⁻³				

Abbreviations: MAF(C), minor allele frequency (count); OR, odds ratio; CI, confidence interval; P, p-value. Variants are annotated in chromosome:base position:non-effect allele:effect allele format, GRCh38 build. **Supplementary Table 13**: Comparing *XNDC1N* rare pathogenic risk allele frequencies among healthy adults (gnomAD, N=16,465) and SJLIFE survivors without diabetes mellitus (N=2,841) and with diabetes mellitus (N=261)

			Allele	Allele		
XNDC1N rare pathogenic variants (rsid)	Study sample	MAF	count	number	OR (95% CI)	Р
chr11:71918924:G:A (rs200142185)	gnomAD: EUR controls	0.0020	14	6850	Reference	
	EUR survivors without DM	0.0012	7	5704	0.60 (0.21-1.60)	0.38
	EUR survivors with DM	0.0096	5	522	4.72 (1.33-13.94)	8.8x10 ⁻³
chr11:71918995:TTTAGCAAGTTCTCTACAGGA:T (rs771623613)	gnomAD: EUR controls	0.0003	2	6848	Reference	
	EUR survivors without DM	0.0009	5	5682	3.01 (0.49-31.66)	0.26
	EUR survivors with DM	0.0057	3	522	19.77 (2.26-236.43)	3.2x10 ⁻³

Abbreviations: Genome Aggregation Database, gnomAD; EUR, European genetic ancestry; DM, diabetes mellitus; rsid, genetic variant identifier using dbSNP build 151; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; P, p-value. Variants are also shown in chr:base position:reference allele:effect allele format, where base position is provided in GRCh38 (hg38) build. P-values are from 2-sided Fisher's exact tests comparing allele counts, using the European (non-Finnish) control/biobank samples in gnomAD v3.1.2.

reid	Chr	BD	ΕA	NEA	Genes within	Functional	CADD	Regulatory function	meOTLs	
rs143578296	2	2434309	A			consequence	6.5		Not available	Not available
rs13436710	5	9843018	с	Т	LINC02112	Intron variant	3.3		Not available	Single-tissue sQTLs: FAM173B (brain- hypothalamus, EAdir=+)
rs6993752	8	50638825	G	A	SNTG1	Intron variant	0.1	CTCF binding site (ENSR00000854839); enhancer (ENSR00001137992)	<i>SNTG1</i> (EAdir=+, Probe=cg17991843)	
rs200142185	11	71918924	А	G	XNDC1N	Incomplete terminal codon variant, coding sequence variant; stop gained	40.0		Not available	Not available
rs771623613	11	71918995	т	TTTAGCAAG TTCTCTACAGGA	XNDC1N	Stop gained, frameshift variant	33.0		Not available	Not available
rs35017858	19	22614854	G	A	LINC01785	Downstream gene variant	5.0		Not available	Single-tissue eQTLs: <i>LINC01785</i> (thyroid, EAdir=-) ZNF723P (testis, EAdir=+) <i>ZNF257</i> (brain nucleus accumbens basal ganglia, EAdir=-) <i>ZNF492</i> (esophagus mucosa, cells cultured fibroblasts, testis, EAdir=-)

Supplementary Table 14: Index variant *in silico* functional annotations

Major abbreviations: rsid, genetic variant identifier, dbSNP build 151; Chr, chromosome; BP: genomic base position, GRCh38 build; EA, effect allele; NEA, non-effect allele; QTL, quantitative trait loci; eQTL, expression QTL; sQTL, splicing QTL; meQTL methylation QTL.

a. Functional consequences were annotated with Ensembl Variant Effect Predictor (VEP v99).

b. Combined Annotation Dependent Depletion (CADD) scores reflect variant deleteriousness, PHRED-scaled such that scores >10 represent variants with the top 10% of CADD scores, >20 with top 1% of CADD scores, etc.

c. Single-tissue eQTLs/sQTLs with FDR<5% were based on BIOS QTL, eQTLGen, and GTEx v8, where top eQTL/sQTL genes are genes with at least one significant (FDR<5%) *cis*-SNP association.

d. BIOS QTL was used to annotate significant (FDR<5%) meQTL variants.

		•	Any pro	moter	Any enhancer		Any	transcription	Any polycomb repressed	
rsid	CHR	BP	Overlapping variants	Relevant epigenomes	Overlapping variants	Relevant epigenomes	Overlapping variants	Relevant epigenomes	Overlapping variants	Relevant epigenomes
rs143578296	2	2434309							chr2:2438081, chr2:2464639, chr2:2466712	LIVER (E066,E118); PANCREAS (E087)
rs13436710	5	9843018							chr5:9843130, chr5:9853144, chr5:9841295	FAT (E063); LIVER (E066); PANCREAS (E087)
rs6993752	8	50638825	chr8:51555678, chr8:51554112	PANCREAS (E087)	chr8:51595171, chr8:51767887, chr8:515588663, chr8:51554112, chr8:5155678, chr8:51631199, chr8:51631400, chr8:51631400, chr8:51627574, chr8:51627574, chr8:51557540, chr8:51557540, chr8:51807451, chr8:51729352	LIVER (E066); PANCREAS (E087)				
rs35017858	19	22614854							chr19:22795650, chr19:22795896, chr19:22797656, chr19:22797775, chr19:22798044, chr19:22798180, chr19:22798234	PANCREAS (E087)
rs200142185	11	71918924					chr11:71629970, chr11:71630041	FAT (E023,E025,E063); LIVER (E066,E118); PANCREAS (E098)		
rs771623613	11	71918995								

Supplementary Table 15: Chromatin state annotations in pancreas-, liver-, and fat-related epigenomes

Chromatin state annotations were taken from the 15-state (ChromHMM) model based on 12 epigenetic marks for 127 epigenomes (Roadmap Epigenomics Consortium). We used pooled chromatin state annotations for any promoter (states 1-2, 10), transcription (states 3-5), enhancer (states 6-7, 11-12), and polycomb repressed (states 13-14) states among relevant epigenomes (liver [E066, E118]; pancreas [E087, E098]; fat [E023, E025, E063]). Overlapping variants are annotated in Chr:BP format, GRCh37 build; bolded variants correspond to index variants.

Major abbreviations: rsid, genetic variant identifier, dbSNP build 151; Chr, chromosome; BP: genomic base position, GRCh38 build.